This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
We’ve been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE 3-drug combo ombitasvir (ABT-267), paritaprevir (ABT-450)+ritonavir, and dasubuvir (ABT-333) which was developed for Chronic Hepatitis C by pharmaceutical company, AbbVie. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination).
-
For background info see http://hepcbc.bchep.org/contribute-to-abbvie-3d-submission-to-cadth/.
-
For the actual questionnaire, go to: http://hepcbc.bchep.org/questions-cadth-abbvie-3-drug/.
DEADLINE: Thursday, December 18th, 2014 (midnight). -
Please tweet, re-tweet, put on Facebook, and forward this information, thanks!
*CADTH = Canadian Agency for Drugs and Technologies in Health, which does government-requested reviews for Health Canada and the Canadian Drug Review process.